Sign in to view content

Phase III Randomized Clinical Trial Comparing SB15 With Reference Aflibercept in Neovascular Age-Related Macular Degeneration 56-Week Results

Min Sagong, MD

Video
Published 2023

Related

Biosimilar Paradox: How Biosimilar Use Will Increase Patient and Healthcare Costs
Ravi Parikh, MD MPH
Annual Meeting Talks
2023
Primary Analysis Results of the Phase 3 Archway Trial of the Port Delivery System With Ranibizumab (PDS) for Patients With Neovascular AMD
Peter A. Campochiaro, MD
Annual Meeting Talks
2020
Novel Vascular Endothelial Growth-Factor A (VEGF-A) and Angiopoietin-2 (Ang-2) Bispecific Protein, RO-634, in Comparison to Aflibercept
Mark R. Barakat, MD
Annual Meeting Talks
2022

Category: AMD-Neovascular

See more